Drug Detail:Perampanel (Perampanel [ per-am-pa-nel ])
Drug Class: AMPA receptor antagonists
Perampanel Levels and Effects while Breastfeeding
Summary of Use during Lactation
A minimal amount of information is available on use of perampanel during breastfeeding. If perampanel is required by the mother, it is not necessarily a reason to discontinue breastfeeding, but monitor the infant for drowsiness, agitation, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of drugs.
Drug Levels
In published reports of anticonvulsant use during breastfeeding, most women were taking a combination of anticonvulsants. Some other anticonvulsants (e.g., phenytoin, carbamazepine) stimulate the metabolism of other drugs including anticonvulsants, whereas others (e.g., valproic acid) inhibit the metabolism of other drugs. Therefore, the relationship of the maternal dosage to the concentration in breastmilk can be quite variable, making calculation of the weight-adjusted percentage of maternal dosage less meaningful than for other drugs in this database.
Maternal Levels. A mother was taking perampanel 8 mg daily as well as lacosamide 200 mg twice daily and brivaracetam 100 mg twice daily. Her milk perampanel levels were 0.31 micromoles/L (108 mcg/L) on day 5 postpartum 12 hours after the previous dose and 0.15 micromoles/L (52 mcg/L) on week 5 postpartum 13 hours after the previous dose.[1]
Infant Levels. A mother was taking perampanel 8 mg daily as well as lacosamide 200 mg twice daily and brivaracetam 100 mg twice daily. Her infant was exclusively breastfed and had serum perampanel concentration of 0.23 micromoles/L (80 mcg/L) on day 1, 0.49 micromoles/L (171 mcg/L) on day 5, and 0.23 micromoles/L (80 mg/L) in week 5 postpartum, which are near the lower end of the therapeutic range of 0.25 micromoles/L. At week 11 postpartum, the infant was partially breastfed and perampanel was undetectable (<0.15 micromoles/L; <52 mcg/L) in the infant’s serum.[1]
Effects in Breastfed Infants
An infant was exclusively breastfed by a mother taking perampanel, brivaracetam and lacosamide for 6 weeks, then partially breastfed. The infant did not exhibit reduced wakefulness or feeding problems. At one year of age, the mother reported normal development.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Seizure Disorder) Carbamazepine, Divalproex, Gabapentin, Lamotrigine, Oxcarbazepine, Phenytoin, Valproic Acid
References
- 1.
-
Landmark CJ, Rektorli L, Burns ML, et al. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. Epileptic Disord. 2021;23:426–31. [PubMed: 33935028]
Substance Identification
Substance Name
Perampanel
CAS Registry Number
380917-97-5
Drug Class
Breast Feeding
Lactation
Anticonvulsants
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification